Professor
Prof J.G. Hakim
MBChB, MMed, MSC, FRCP (Lond & Edin)
E-mail : This email address is being protected from spambots. You need JavaScript enabled to view it.
Publications:
Robertson K, Jiang H, Kumwenda J, Supparatpninyo K, Evans S, Campbell TB, Price R, Tripathy S, Kumarasamy N, La Rosa A, Santos B: the 5199 study team, Silva MT, Montano S, Kanyama C, Faesen S, Murphy R, Hall C, Marra CM, Marcus C, Berzins B, Allen R, Housseinipour M, Amod F, Sanne I, Hakim J, Walawander A, Nair A; the AIDS Clinical Trials Group. Improved Neuropsychological and Neurological Functioning Across Three Antiretroviral Regimens in Diverse Resource-Limited Settings: AIDS Clinical Trials Group Studay A5199, the International Neurological Study. Clin Infect Dis. 2012: 55:868-876
Medina Lara A, Kigozi, Amurwon J, Muchabaiwa L, Nyanzi Wakaholi B, Mujica Mota RE, Walker AS, Kasirye R, Ssali F, Reid A, Grosskuth H, Babiker AG, Kityo C, Katabira E, Munderi P, Mugyenyi P, Hakim J, Darbyshire J, Gibb DM, Gilks CF; DART Trial Team. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One 2012; 7(4):e33672.
Kiwuwa-Muyingo S, Walker AS, Oja H, Levin J, Miiro G, Katabira E, Kityo C, Hakim J, Todd J; the DART Trial Team. The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda andTrop Med Int Health. 2012 March 30. Doi: 10.1111/j.1365-3156. 2012.02974 .x.
Kuritzkes D.R, Hakim J.G, Sanne I. Least among equals. Clin Infect Disease. 2012; 54: 876-7
Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinz Al, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study team to the ACTG. Efficacy and Safety of Three Antiretroviral Regiments for Initial Treatment of HIV-1: A randomized Clinical Trial in Diverse Multinational Settings,. PLoS Med. 2012 (8): e1001290.
Gibb DM, Kizito H, Russel EC, Chidziva E, Zalwango E, Nalumenya R, Spyer M, Tumukunde D, Nathoo K, Mundeti P, Kyomugisha H, Hakim J, Grosskurth H, Gilks CF, Walker AS, Musoke P; DART trial team. Pregnancy and infant outcomes among HIV-Infercted women taking long term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9 (5): e1001217
Stohr W, Reid A, Walker AS, Ssali F, Munderi P, Mambule I, Kityo C, Grosskurth H, Gilks CF, GibbDM, Hakim J; DART Trial Team. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antivir Ther. 2011;16:1011-20
Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells, Qasba SS Luetmemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N ENGL J Med. 2011;365:
Robertson K, Kumwenda J, Supparatpinyo K, Jiang JH, Evans S, Campbel TB, Price RW, Murphy R, Hall C, Marra CM, Marcus C, Berzins B, Masih R, Santos B, Silva MT, Kumarasamy N, Walawander A, Nair A, Tripathy S, Kanyama C, Hosseinipour M, Montano S, La Rosa A, Amond F, Sanne I, Firnhaber C, Hakim J, Brouwers P, AIDS Clinical Trials Group. A multinational study of neurological performance in antiretroviral therapy-naive HIV-1 infected persons in diverse resource-constrained settings. J Neurovirol. 2011;17:438-47
Sibanda EL, Weller IV, Hakim JG, Cowan FM. Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clin Infect Dis.2011;52:1184-94
Hakim J.G, Matenga J.A, Havranek E, Kao D, Health Workforce development with a focus on cardiovascular disease in Zimbabwe; CHRIS Program, a medical education partnership initiative. Global Heart 2011;6 (4)219-220.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim J.G, Kumwenda J, Grinsztejn B, Pilotto JHS, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IFP, Elshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Rivaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Flemming TR, for the HPTN 052 Study Team. Prevention of HIV-1 Infection with Early antiretroviral therapy. N Engl J Med. 2011; 365:493-505.
Grinsztejn B, Smeaton L, Barnett R, Klingman K, Hakim J, Flanigan T, Kuramarasamy N, Campbell T, Currier J, PEARLS study team of the ACTG. Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4 (+) T-Cell count. Antivir Ther. 2011; 16:1057-62
Havlir DV, Kendall M.A, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hoff E, Rooney JF, Wu X, Hosseinipour MC, Lallo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe R, Andersen J, Sanne I; AIDS Clinical Trials Group Study A5221. Timing of ART therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011; 365:1482-91
Eshleman SH, Hudelson SE, Redd AD, Wang L, Debes R,Chen YQ, Martens CA, Ricklefs SM, Selig EJ, Porcella SF, Munshaw S, Ray SC, Piwowar-Minning E, McCauley M, Hosseinipour MC, Kumwenda J, Hakim J, Chariyalertsak S, de Bruyn G, Grinsztejn B, Kumarasamy N, Makhema J, Mayer KH, PilottoJ, Santos BR, Quinn TC, Cohen MS, Hughes JP. Analysis of genetic linkage of HIV from couples enrolled in the HPTN 052 trial. J Infect Dis. 2011; 204:1918-26
Campbel TB, Smeaton LM, Kumarasamy N, FlaniganT, KlingmanKL, FirnhaberC, Grinsztejn B, Hosseinpour MC, Kumwenda J, Lallo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez Al, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim J.G; PEARLS study team of the ACTG. Efficacy and Safety of three antiretroviral Regimens for Initial Treatment of HIV-1: A Randomised Clinical Trial in Diverse Multinational Settings. PLoS Med. 2012 (8):e 1001290.
Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, Spyer M, Tumukunde D, Nathoo K, Munderi P, Kyomugisha H, Hakim J, Grosskurth H, Gilks CF, Walker AS, Musoke P; DART trial team. Pregnancy and infant outcomes among HIV-infected woman taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012; 9(5):e1001217.